市場調查報告書
商品編碼
1119087
便秘治療全球市場規模研究:按治療劑、疾病類型(慢性特發性便秘、腸易激綜合徵便秘、阿片類藥物引起的便秘)、分銷渠道、地區預測 2022-2028Global Constipation Treatment Market Size study, by Therapeutic, Disease Type (Chronic idiopathic constipation, irritable bowel syndrome with constipation, and Opioid-induced constipation ), Distribution Channel, and Regional Forecasts 2022-2028 |
在 2022-2028 年的預測期內增長 9%。
便秘是持續數週或更長時間的不規則排便和硬便的持續狀態。每周少於 3 次大便被認為是嚴重便秘,每周少於 1 次大便也是如此。便秘會導致排便疼痛、排便困難、排便不規則和腸道通道阻塞。急性便秘也會阻塞腸道並需要手術。腹脹、小腹不適、直腸出血、大便硬而肛裂、排便困難、胃痛、排便用力,都是便秘的徵兆。因為它是一種特發性疾病,病因不明。市場受到主要因素的推動,例如最新藥物和治療方法的開發、老年人口的增加以及飲食習慣的改變。例如,根據美國疾病控制和預防中心 2021 年 11 月的數據,OIC 處方數量在 2019 年增加到 153,260,450 份,到 2020 年增加到 142,816,781 份。越來越多的服用阿片類藥物的患者將推動對一種稱為阿片類藥物誘導的便秘( OIC )的有效治療的需求,預計這將在整個預測期內推動便秘治療市場。此外,從 2015 年到 2050 年,全球 60 歲及以上的人口將幾乎翻一番,從 12% 增加到 22%。據世界衛生組織稱,到 2030 年,地球上六分之一的人將超過 60 歲。此外,在醫療保健領域不斷增長的投資將在未來幾年提供重要的商機。然而,在 2022-2028 年的預測期內,對大多數非處方 (OTC) 藥物的日益依賴正在阻礙市場增長。
全球便秘治療市場研究考慮的主要地區包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。由於老年人口不斷增加,亞太地區引領全球市場份額。然而,由於最新藥物和治療方法的開發,預計北美將成為增長最快的地區。
本報告中包括的主要市場進入者是:
本研究的目的是確定近年來各個細分市場和國家的市場規模,並預測未來八年的價值。本報告旨在捕捉所調查的每個地區和國家的行業的定性和定量方面。此外,它還提供了有關關鍵方面的詳細信息,例如定義市場未來增長的驅動因素和挑戰。此外,該報告還應納入微觀市場中可供利益相關者投資的可用機會,以及對競爭格局和主要參與者的應用產品的深入分析。市場的詳細細分和子細分如下所述。
按藥物
瀉藥
氯離子通道激活劑
外周作用的 Mu-阿片受體拮抗劑
其他
按疾病類型
慢性特發性便秘(CIC)
便秘型腸易激綜合徵(IBS-C)
阿片類藥物引起的便秘 (OIC)
按銷售渠道
醫院藥房
零售藥店
網上藥店
按地區
北美
美國
加拿大
歐洲
英國
德國
法國
西班牙
意大利
歐洲其他地區
亞太地區
中國
印度
日本
澳大利亞
韓國
其他亞太地區
拉丁美洲
巴西
墨西哥
世界其他地區
此外,本研究考慮的年份是:
實際年份 - 2018 年、2019 年、2020 年
2021 年基準年
預測期 - 2022-2028
本報告的目標受眾是全球便秘治療市場。
主要諮詢公司和顧問
大公司、中型公司、中小企業
風險投資
增值經銷商 (VAR)
第三方知識提供者
投資銀行家
投資者
Global Constipation Treatment Market is valued at approximately USD XXX million in 2021 and is anticipated to grow with a healthy growth rate of more than 6.9% over the forecast period 2022-2028. Constipation is a constant condition that results in irregular bowel motions and hardened faeces that last for a few weeks or even longer. Having less than three stools per week is considered severe constipation, as is having fewer than one stool per week. It results in painful and stiff bowel movements, irregular stools, and difficult bowel passage. The intestines may become blocked because of acute constipation, necessitating surgery in some cases. Bloating, lower abdominal discomfort, rectal bleeding, anal fissures brought on by hard stools, inadequate evacuation, gastric pain, and straining during bowel movements are all signs of constipation. The causes of this disease are unknown because it is an idiopathic condition. The market is driven by the key factors such as development of Latest Drugs and Treatment Procedures and increasing Geriatric Population and Changing Dietary Habits. For instance, the number of OIC prescriptions grew by 153,260,450 in 2019 and 142,816,781 in 2020, according to the Centers for Disease Control and Prevention in November 2021. The increasing number of patients who take opioids necessitates effective treatment for conditions known as opioid-induced constipation (OIC), which is expected to drive the market for treatments for constipation throughout the projected period. furthermore, the global population aged 60 and up is nearly double from 12 percent to 22 percent from 2015 to 2050. Also, as per WHO, by 2030, 1 out of every 6 people on the planet will be 60 and above aged. Moreover, growing investment in healthcare creates lucrative opportunities in the upcoming years. However, increasing dependence on majority of over the counter (otc) drugs impedes the growth of the market over the forecast period of 2022-2028
The key regions considered for the global Constipation Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific is leading the global market share owing to rise in geriatric population. However, North America is expected to be the fastest growing region due to Development of Latest Drugs and Treatment Procedures in the region.
Major market players included in this report are:
Takeda Pharmaceutical Company Ltd.
Valeant Pharmaceuticals International Inc.
Ironwood Pharmaceuticals, Inc.
Pfizer Inc.
Salix Pharmaceuticals, Inc.
Abbott Laboratories
Bayer AG
Sanofi S.A.
Janssen Pharmaceutical Company
Cosmo Pharmaceuticals NV
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapeutics:
Laxatives
Chloride Channel Activators
Peripherally Acting Mu-Opioid Receptor Antagonists
Others
By Disease Type:
Chronic Idiopathic Constipation (CIC)
Irritable Bowel Syndrome with Constipation (IBS-C)
Opioid-Induced Constipation (OIC)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019, 2020
Base year - 2021
Forecast period - 2022 to 2028
Target Audience of the Global Constipation Treatment Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
List of figures